StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Bristol-Myers' (BMY) Lack of Suitor Positive for Celgene (CELG) Deal - Baird
March 12, 2019 1:34 PM
Baird analyst Brian Skorney reiterated an Outperform rating and $101.00 price target on Celgene (NASDAQ: CELG), saying they are positive ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Mergers and Acquisitions
Rumors
Next Articles
Bristol-Myers (BMY) Had Informal, High Level Past Deal Talks with Others; Past Talks Had no Terms, were Informal, no Offers - Bloomberg, Citing CEO
March 12, 2019 11:54 AM
Third Point, DE Shaw Not Involved with Celgene (CELG)/Bristol-Myers (BMY) - CNBC
March 12, 2019 9:49 AM